NCT01887106 - First-in-Human Single and Multiple Dose of GLPG1205 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

October 31, 2013

Conditions

Healthy

Interventions

DRUG

GLPG1205 single ascending doses, oral suspension

Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg

DRUG

Placebo single ascending doses, oral suspension

Single dose, oral suspension matching placebo

DRUG

GLPG1205, multiple ascending doses, oral suspension

Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg

DRUG

Placebo, multiple ascending doses, oral suspension

Multiple doses, daily for 14 days, oral suspension matching placebo

Trial Locations (1)

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp